In this work, we explored the role of cyclic nucleotides in modulating parameters of the Na/H antiport in human platelets. Sodium nitroprusside and iloprost, as well as cyclic nucleotide analogues, were used to raise cellular levels of cAMP and cGMP. Cyclic nucleotides reversed the thrombin-evoked alkaline shift in cytosolic pH set point and the activity of the Na/H antiport, concurrently with attenuation of thrombin-induced rise in cytosolic free Ca. No effect of cyclic nucleotides was observed in platelets not treated with thrombin, or platelets subjected to phorbol 12-myristate 13-acetate. cAMP did not reverse ionomycin-induced changes in the parameters of the Na/H antiport. Collectively, these observations indicate that cyclic nucleotides modulate the Na/H antiporter in human platelets through their effect on thrombin-evoked changes in cytosolic free Ca. Presumably, this effect holds for other agonists which stimulate phospholipase C, raise cytosolic-free Ca, and activate the Na/H antiport through protein kinase C dependent and protein kinase C-independent mechanisms. (J.
Introduction
Activation ofplatelets by a variety ofagonists is associated with stimulation of the Na/H antiport (1) (2) (3) . This mode of activation of the Na/H antiport usually entails stimulation of phospholipase C (PLC),' a rise in cytosolic-free Ca (Ca,), and stimulation of protein kinase C (PKC) (3-5; for review, see reference 6) . However, it can proceed through PKC-independent mecha-1. Abbreviations used in this paper: Bt2cAMP, dibutyryl cAMP; Cai, cytosolic-free Ca; 8BrcGMP, 8 bromo cGMP; HBS, HEPES-buffered solution; pHi, cytosolic pH; PLC, phospholipase C; PKC, protein kinase C; PMA, phorbol 12-myristate 13-acetate; SNP, sodium nitroprusside; Xi, the set point for activation ofthe Na/H antiport; Zi, activity index. nisms. The Na/H antiport can also be activated without an apparent rise in Cai, or stimulation ofPLC. For instance, phorbol esters circumvent PLC by activating the Na/H antiport through direct stimulation ofPKC (2, (7) (8) (9) (10) . Irrespective ofthe pathway of agonist-evoked stimulation of the Na/H antiport, this process is accomplished by an alkaline shift in the cytosolic pH (pHi) set point for activation, by increased activity of the Na/H antiport within a given pH range, or by both mechanisms (2, 6) .
In a previous study, we showed that Cai is central to agonist and nonagonist-mediated activation of the Na/H antiport in human platelets, and that the effect of Cai predominates over that of PKC (2) . Cyclic nucleotides are cellular messengers that inhibit platelet aggregation and diametrically antagonize Cai in these cells (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) . We have thus focused this investigation on the role of cyclic nucleotides in modulating parameters of the Na/H antiport. Our results indicate that cyclic nucleotides exert their effect on the Na/H antiport primarily through Cai.
Methods
Platelet preparation 50 ml ofblood were drawn from each subject into acid dextrose buffer (20:1, vol/vol) consisting of (mM) sodium citrate 14, citric acid 11.8, and dextrose 18 (final pH 6.5). Platelet-rich plasma was obtained by centrifugation at 200 g for 10 min at room temperature. It was then centrifuged at 1,000 g for 10 min, and cells were washed three times (using centrifugations at 1,000 g) with buffer consisting of(mM) NaCl 140, KCl 5, glucose 10, EGTA 0.2, Hepes 10, and (unless otherwise indicated) acetylsalicylic acid (aspirin) 0.1. BSA (0.1I%) was added to the third washing, and EGTA was deleted. BSA was included in all subsequently used solutions, except the dye loading buffer. Aspirin was used in most platelet preparations because (a) Cai and pH, signals pendent protein kinase inhibitor KT5720 (Kamiya Biochemical Corp., Thousand Oaks, CA). Other platelets were treated with the various agonists and probes before and during cellular acidification and other experimental manipulations. For cellular acidification, 80 gl of dyeloaded platelets in Na-free HBS (N-methyl-D-glucamine replacing Na) were injected into cuvettes containing 3 ml HBS (in which 20-140 mM Na propionate equimolarly replaced NaCl; pH 7.4), with or without thrombin and other agents. Whenever indicated, platelets were preincubated in HBS containing these agents before their injections into the cuvette, which also contained these agents in HBS. Cellular buffering power was determined as previously described (2 Data analysis. Initial rates for the pHi recovery from acidification were derived from iterative curve fittings, as described previously (18) . These rates represent the activity ofthe Na/H antiport, inasmuch as the recovery was Na-dependent and sensitive to amiloride analogues. The initial rates demonstrate a linear relationship with the initial pH, when the latter parameter is expressed as cellular proton concentration. The x-axis intersect of the linear regression describing the initial rates of recovery from acidifications as a function of the cellular proton concentration represents the set point, and the slope ofthe line the activity index (Zi) of the Na/H antiport. When expressed in pH units, the set point for activation of the Na/H antiport is termed Xi (for further details, see reference 2). One-way analysis of variance (ANOVA) was used in data analysis. All computations were performed with an IBM compatible PC (SAS REG and GLM programs; SAS Institute, Cary, NC). Data are presented as mean or mean±SEM. Unless indicated, platelets from at least four subjects were used for each experimental protocol.
Results
No statistically significant differences were observed in pH, and Ca, under basal or stimulated states between aspirin-treated platelets and platelets not treated with aspirin. For instance, the basal pHi for platelets not treated with aspirin was 7.097±0.014
(not shown). The basal pH, levels of aspirin-treated platelets used in experimental protocol described in Figs. 1-4, were 7.138±0.013,7.099±0.023,7.123±0.012, and 7.096±0.028, respectively. The effects of the various treatments on Xi or Zi were also equivalent in aspirin-treated platelets and platelets not treated with aspirin. Thus, all further experiments were performed in aspirin-treated platelets.
In general, treatment with thrombin produced transient acidification, followed by alkalinization, and a Cai transient that was followed by sustained elevation (compared with basal level) of the posttransient Ca,. Fig. 1 summarizes experiments designed to explore the effect of Bt2cAMP on the thrombin-evoked responses, and the potential effect ofPKC inhibition by staurosporine on this process. In itself, thrombin produced an alkaline shift in the Xi, an increase in Zi, and an increase in the Ca,. The thrombinevoked alkaline shift in the Xi was reversed, and the thrombininduced rise in Zi attenuated by treatment with Bt2cAMP. In nonacidified platelets, the alkalinization produced by thrombin was also reversed by Bt2cAMP. Likewise, the thrombin-induced Ca, transient and posttransient Ca dependent protein kinase. To rule out the possibility that the effect of staurosporine is exerted through inhibition of cAMPdependent kinase, platelets were preincubated for 5 min with 1 ,uM of KT5720, which is an inhibitor of the enzyme. At this concentration, there is little effect ofKT5720 on PKC, yet its K, for cAMP-dependent protein kinase is -0.05 gM (19, 20) .
There was no apparent effect of KT5720 on the thrombin-induced cellular response (Fig. 2) . To further examine the relationship between cyclic nucleotides and PKC, platelets were treated with the phorbol ester PMA and Bt2cAMP. As shown in Fig. 3 , 100 nM of PMA produced an alkaline shift in the Xi from 6.903 to 7.066, and a 67% increase in the Zi. These alterations were not reversed by 3 mM Bt2cAMP (Xi in the presence of Bt2cAMP and PMA = 7.062). There was no effect of PMA on Ca, (not shown). It is noteworthy that in this set of experiments, PMA, like thrombin, induced a transient cellular acidification followed by sustained alkalinization (Fig. 3, bottom) .
Iloprost is a stable prostacyclin analogue, and it promotes inhibition ofplatelet aggregation by raising endogenous cAMP (21) (22) (23) . It was thus used to examine the effect of cAMP on thrombin-evoked alteration in platelet Na/H antiport parameters. The effect of 10 nM iloprost was the same as that of Bt2cAMP, i.e., reversing the thrombin-induced alkaline shift in Xi (control = 6.926; thrombin = 7.070; thrombin plus iloprost = 6.935) and attenuating the increase in Zi (Fig. 4, left) . These effects were accompanied by substantial attenuations of the pH, (alkalinization) and Ca, responses to thrombin (Fig. 4,   right) . Thrombin-induced alkaline shift ofXi and increase in Zi of the Na/H antiport were also attenuated by 5 mM 8BrcGMP (Fig. 5 ) and 5 mM SNP (Fig. 6) . The latter compound stimulates guanylate cyclase to raise the endogenous levels ofplatelet cGMP and inhibits platelet aggregation (11, 12, 24, 25) . These effects ofendogenous and exogenous cGMP were coupled with marked inhibitions of the Ca, and pHi responses to thrombin (Figs. 5 and 6, right).
Both Bt2cAMP (Fig. 7) and SNP ( Fig. 8) Nonagonist-mediated elevation of Ca, (produced by 500 nM ionomycin in 1 mM HBS) caused an alkaline shift in the Xi from 6.908 to 7.263, and a threefold increase in the Zi (Fig.  9, left) . Bt2cAMP neither reversed the ionomycin-induced alkaline shift in Xi (in the presence ofBt2cAMP and ionomycin, Xi = 7.239) nor attenuated the increase in Zi. Moreover, there was no effect of the cyclic nucleotide on ionomycin-evoked changes in the pHi and Ca, profiles in nonacidified platelets (Fig. 9, right) .
Finally, there was no effect of the various probes on the cellular buffering power (control = 23.9±0. 41 
Discussion
Cyclic nucleotides, i.e., cAMP and cGMP, inhibit agonistevoked platelet aggregations (12, 23, 26) . This inhibition is mediated through lowering the Ca, (11) (12) (13) (14) (15) (16) 27 ) and via Ca-independent mechanisms (28) . Blunting 'or ablating of agonistevoked Cai response by cyclic nucleotides involve key elements ofCa, homeostasis, including inhibition of(a) agonist-receptor interaction (29) ; (b) PLC (11, 12, 30, 31) ; (c) Ca mobilization from intracellular organelles (26, 27, 30, 32) ; and (d) Ca uptake from the extracellular compartment (27, 30, 32). Additionally, cyclic nucleotides stimulate Ca sequestration (33) . Irrespective of the specific mechanisms by which cyclic nucleotides lower the Ca,, cAMP and cGMP do not lower Ca, in platelets under basal conditions, or when the Ca1 is raised by Ca ionophores, as has been demonstrated here by us and by others (26, 28, 30, 34) .
The central conclusion emerging from the present work is that the effects ofcAMP and cGMP on parameters ofthe Na/H antiport are exerted through attenuation ofthe Ca, response to thrombin. These agents had no effect on the Xi, Zi, and pH, profile under circumstances in which they did not modulate the Ca, (e.g., basal conditions, treatment with ionomycin, treatment with PMA). Moreover, the Xi manifests greater sensitivity to cyclic nucleotides than the Zi. In previous work, we suggested that the Xi and Zi demonstrate different dependencies on Ca, (2) . It is thus possible that the Na/H antiport exhibits more than one mode of operation at various Ca, levels, or that more than one isomer ofthis transport system exists in human platelets.
The inability of cyclic nucleotides to completely block the thrombin-evoked rise in the Zi appears unrelated to thrombininduced stimulation of PKC. Inhibition of PKC, in fact, produced a further alkaline shift in the Xi in thrombin and Bt2cAMP-treated platelets. This is likely to relate to the further rise in the Ca, in response to thrombin in platelets treated with staurosporine (for further details, see reference 2). It is possible, however, that because of its nonspecificity, staurosporine not only inhibited PKC but also cAMP-dependent protein kinase. Thus, treatment with staurosporine could blunt cAMP action if it is mediated through cAMP-dependent protein kinase. The use of the specific inhibitor of this enzyme (KT5720) showed that this was not the case.
Inhibition ofthe Na/H antiport by cAMP has been demonstrated in other cells, such as epithelia of the urinary system (35) (36) (37) (38) , and in osteoblast-like cells (39) . Thus, agents known (43) (44) (45) (46) (47) , a phenomenon that may reflect reduced maxinbin increased the pH, mal initial reaction velocity for Ca activation ofthe Ca-ATPase io s. In SNP-treated in the plasma membrane ofthese cells (48) . Moreover, platelets to 7.148 at 300 s, and from essential hypertensives exhibit lower cAMP levels (49) . q at 20 s, and to 65. 5 These observations suggest an explanation for increased platelet Na/H antiport activity in essential hypertension (50-52).
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-0 fiT& i1 4 AT&L Likewise, a recent study has demonstrated that diabetes in the rat is expressed by an alkaline shift of the Xi in hepatocytes (53), a pertubation that may also relate to an imbalance between Ca, and cyclic nucleotides.
In conclusion, the present work demonstrates that cyclic nucleotides modulate the Na/H antiport through Ca,. It also confirms our previous observation that Ca, is paramount to agonist and nonagonist-mediated activation of the Na/H antiport in human platelets, exerting its effect both on the Xi and Zi.
